LONDON, July 5, 2026, 17:01 BST
- Cirata ended Friday at 17.90p, gaining 6.87%. The FTSE AIM All-Share slipped 0.17%.
- The stock closed up 19.3% from the 15p issue price set at last week’s conditional fundraising.
- Cirata will ask shareholders July 24 to approve a 36.31 million new share issue, equal to 28.7% of current equity. If approved, the shares are set to start trading July 28.
Cirata Plc (LON:CRTA) saw its last trade on Friday, since London markets are shut on Sunday. The stock ended the week a bit above the new equity raise price. Investors go into the new week with that gap giving some idea how much dilution they’ll put up with.
Cirata finished the July 3 session at 17.90p, gaining 6.87% with 54,812 shares moved. The FTSE AIM All-Share lost 0.17% to close at 776.09 the same day. Cirata now stands 19.3% over the 15p fundraising price, though still far from AJ Bell’s posted high of 29p for the year.
The key issue is the stock-to-flow gap. Cirata’s plan for 36.31 million new shares is about 662 times the volume reported on Friday. That doesn’t mean the company will sell all the new stock, but July 28, the expected admission date, is likely to be a price event and will also hit the balance sheet.
| Market marker | Latest reading | Investor read |
|---|---|---|
| Cirata closed Friday at 17.90p, up 6.87% | 17.90p, +6.87% | That’s 19.3% higher than the 15p raise price |
| Friday turnover | 54,812 shares | Issued shares from the raise are about 662 times Friday’s volume |
| FTSE AIM All-Share | 776.09, -0.17% | Cirata outperformed by nearly 7 percentage points |
| AJ Bell’s annual range | 12.50p-29.00p | Friday’s finish was 43.2% above the year’s low, still 38.3% off the high |
Cirata said June 29 it had raised around £5.1 million gross from a placing and subscription, and another £0.32 million via a retail offer. Cirata is set to issue 36,310,971 new shares at 15p each. This will bring its issued share capital to 162,759,626 shares with one vote apiece after admission.
| Fundraising item | Company figure | Market math |
|---|---|---|
| Placing and subscription | £5.1 mln gross | 34.16 mln shares |
| Retail offer | £0.32 mln gross | 2.16 mln shares |
| Combined raise | £5.4 mln gross | About 18.5% of pro-forma equity value at 17.90p |
| New shares | 36.31 mln | 22.3% of enlarged share capital |
| Enlarged share capital | 162.76 mln shares | Implied value about £29.1 mln at Friday close |
Cash is in focus with Cirata’s 2025 accounts still showing little room for error. The company posted FY25 revenue of $13.6 million, up 77%. Adjusted EBITDA loss narrowed 74% to $3.8 million. Cash and cash equivalents fell to $4.0 million at Dec. 31 from $9.7 million the previous year. Directors flagged a material uncertainty on going concern in the accounts.
Chief Executive Stephen Kelly said in the June 25 fundraising update that Cirata had reached its first “triple-digit sales growth year” and was operating at “less than 30%” of peak costs. The filing said the company planned to use the $6 million raised in three equal $2 million amounts: for balance-sheet support, turning pipeline into revenue, and investing in Cirata Symphony. Investegate
That move puts Symphony at the core of the equity story. Cirata said June 16 that International Business Machines Corporation NYSE:IBM will now offer Cirata Symphony as Cirata Symphony for IBM Big Replicate, through a revised OEM deal. Kelly said customers want “trusted data that moves continuously and without disruption.” The announcement didn’t give a contract value. Investegate
Fidelity’s Cirata page shows the most recent press releases as the June 29 circular and retail offer result. That follows the June 26 placing and subscription result, and the June 16 IBM OEM agreement. The page states the next expected company report is half-year results in September.
Key dates listed in the circular: Proxy votes must arrive by 11:00 a.m. on July 22. The general meeting will take place at 11:00 a.m. on July 24. Trading in the new shares is due to begin at 8:00 a.m. on July 28.
